Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?

Clinical and Experimental Rheumatology

Volumn 27, Issue 3 SUPPL. 54, 2009, Pages

  Pakozdi, Angela ^a   Wilson, Helen ^a   Black, Carol M ^a   Denton, Christopher P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Gastroesophageal dysmotility; Lansoprazole; Systemic sclerosis

Indexed keywords

LANSOPRAZOLE; PLACEBO; TECHNETIUM TIN COLLOID TC 99M;

ACNE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS MOTILITY; ESOPHAGUS SCINTISCANNING; FEMALE; HEARTBURN; HIP PAIN; HUMAN; LONG TERM CARE; LOOSE FECES; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SELF REPORT; STOMACH PAIN; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; DISEASE PROGRESSION; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMPS; QUESTIONNAIRES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 70350306578     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. CLEMENTS PJ, BECVAR R, DROSOS AA, GHATTAS L, GABRIELLI A: Assessment of gastrointestinal involvement. Clin Exp Rheumatol 2003; 21 (Suppl. 29): S15-18.
2. DIENER U, PATTI MG, MOLENA D, FISICHELLA PM, WAY LW: Esophageal dysmotility and gastroesophageal reflux disease. J Gastrointest Surg 2001; 5: 260-265 (Pubitemid 33652070)
3. KAYE SA, SIRAJ QH, AGNEW J, HILSON A, BLACK CM: Detection of early asymptomatic esophageal dysfunction in systemic sclerosis using a new scintigraphic grading method. J Rheumatol 1996; 23: 297-301.
4. PEURA DA, KOVACS TO, METZ DC, SIEPMAN N, PILMER BL, TALLEY NJ: Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 2004; 116: 740-748
5. DIMENAS E, GLISE H, HALLERBACK B, HERNQVIST H, SVEDLUND J, WIKLUND I: Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28: 681-687
6. REVICKI DA, WOOD M, WIKLUND I, CRAWLEY J: Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7: 75-83.
7. LOCKE GR, 3RD, TALLEY NJ, FETT SL, ZINSMEISTER AR, MELTON LJ, 3RD: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-1456
8. AKESSON A, GUSTAFSON T, WOLLHEIM F, BRISMAR J: Esophageal dysfunction and radionuclide transit in progressive systemic sclerosis. Scand J Rheumatol 1987; 16: 291-9.
9. LEUNG WK, WU JC, CHAN FK et al.: Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: a randomized controlled trial with 12-month follow-up. Am J Gastroenterol 2007; 102: 1483-1488
10. BESTETTIA, CAROLA F, CONCIATO L, MARASINI B, TAROLO GL: Esophageal scintigraphy with a semisolid meal to evaluate esophageal dysmotility in systemic sclerosis and Raynaud's phenomenon. J Nucl Med 1999; 40: 77-84.